They state: “Previous attempts of correcting these areas with fillers showed that subcutaneous ridges or overcorrection may be generated in relation with the rheological properties of previous HA fillers ”
In consequence of this, an innovative manufacturing technology for producing novel HA fillers was developed – MaiLi’s OxiFree™ technology, launched by Sinclair. The core strength of this technology lies in the cross-linking of HA under inert atmosphere, which is followed by extracting reactive oxygen species during the manufacturing process.
Each of the four centres were invited to recruit five patients to be injected with MaiLi Precise using intradermal injections, with multiple punctures, evenly spaced 1-3 mm apart, using a superficial 1-2 mm intradermal needle insertion. The volume injected depended on the desired effect. Follow-up visits were scheduled at one month and three months’ post-injection. All subjects were women, and their average age was 56 years old. Treatment effectiveness was evaluated using the Global Aesthetic Improvement Scale (GAIS), as was the satisfaction of the subjects and investigators. Adverse Events (AEs) were also reported.
After the first month visit, 95% of patients agreed that they were more satisfied with their appearance after MaiLi treatment; 90% were more satisfied after three months. Moreover, 90% of patients indicated that they felt better after the treatment, and that they were satisfied with the smoothness of their skin after one month, while 95% indicated the same after three. All patients agreed that they were more satisfied with the appearance of their wrinkles and of the area treated after MaiLi treatment.
